Heteroaromate OSC inhibitors

Details Heteroaromate OSC inhibitors Heteroaromate OSC inhibitors

2005-10-04

2005-10-04

McKane, Joseph K. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S207000

Reexamination Certificate

active

06951879

ABSTRACT:
The present invention relates to heteroaromate OSC inhibitors. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.

REFERENCES:
patent: 4410539 (1983-10-01), Cross et al.
patent: 5994371 (1999-11-01), Black et al.
patent: 39 05 364 (1990-08-01), None
patent: 778 271 (1997-06-01), None
patent: WO 98/21188 (1998-05-01), None
Gotto et al., Circulation 81, pp. 1721-1733 (1990).
Stein et al., Nutr. Metab. Cardiovasc. Dis. 2, pp. 113-156 (1992).
Illingworth, Med. Clin. North Am. 84, pp. 23-42 (2000).
Ross et al., Arch. Intern. Med. 159, pp. 1793-1802 (1999).
Ellen et al., J. Cardiol. 81, pp. 60B-65B (1998).
Shepherd, Eur. Heart J. 16, pp. 5-13 (1995).
Davignon et al., Can. J. Cardiol 8, pp. 843-864 (1992).
Pedersen et al., Drug Safety 14, pp. 11-24 (1996).
Morand et al., J. Lipid Research 38, pp., 373-390 (1997).
Mark et al., J. Lipid Research 37, pp. 148-158 (1996).
Peffley et al., Biochem. Pharmacol 56, pp. 439-449 (1998).
Nelson et al., J. Biol. Chem. 256, pp. 1067-1068 (1981).
Spencer et al., J. Biol. Chem. 260, pp. 13391-13394 (1985).
Panini et al., J. Lipid Research 27, pp. 1190-1204 (1986).
Ness et al., Arch. Biochem. Biophys. 308, pp. 420-425 (1994).
Janowski et al., Proc. Natl. Acad. Sci. USA 96, pp. 266-271 (1999).
Venkateswaran et al., J. Biol. Chem. 275, pp. 14700-14707 (2000).
Costet et al., J. Biol. Chem. 275, pp. 28240-28245 (2000).
Ordovas et al., Nutr. Rev. 58, pp. 76-79 (2000).
Schmitz et al., Front. Biosci 6, D505-D514 (2001).
Tobin et al., Mol. Endocrinol. 14, pp 741-752 (2000).
Marshall et al., J. Org. Chem. 61(17), pp. 5729-5735 (1996).
Baker et al., J. Chem. Soc. Perkin Trans. 1, pp. 1415-1421 (1990).
Belostotskii et al., Tetrahedron Letters 35(28), pp. 5075-5076 (1994).
Wolfe et al., J. Org. Chem., 65(4), pp. 1158-1174 (2000).
Palucki et al., J. Am. Chem. Soc., 119(14), pp. 3395-3396 (1997).
Denton et al., Synlett, No. 1, pp. 55-56 (1999).
Chaplinski et al., Angew. Chem. Int. Ed. Engl., 35, pp. 413-414 (1997).
Mattson et al., J. Org. Chem., 55, pp. 2552-2554 (1990).
Stara et al., Collect. Czech. Chem. Commun. 64(4), pp. 649-672 (1999).
P.E. Cross, et al,Journal of Medicinal Chemistry, 29(9), pp. 1637-1643 (1986).

Affiliated with

Also associated with

Rating

Heteroaromate OSC inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heteroaromate OSC inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaromate OSC inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3458332